SEAS remain rough for Vytorin
This article was originally published in Scrip
Executive Summary
Pressure onMerck/Schering-PloughPharmaceuticals Vytorin (ezetimibe plus simvastatin) is set to continue after the SEAS study showed that the combination hypolipaemic product failed to reach its primary endpoint in a new indication of aortic stenosis, and was associated with an increased risk of developing cancer.